This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Gentium Presents Additional Efficacy And Safety Data On Defibrotide At The American Society Of Hematology

VILLA GUARDIA, Italy, Dec. 7, 2010 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that three abstracts on Defibrotide were presented at the 52 nd Annual Meeting and Exposition of the American Society of Hematology held at the Orange County Convention Center in Orlando, Florida, December 4-7, 2010.

Dr. Paul Richardson, Clinical Director of the Dana-Farber Cancer Institute, Boston, MA (USA), reported in an oral presentation the results of an interim analysis of the ongoing Treatment IND (T-IND) Expanded Access Protocol. The interim analysis reported results of 104 patients with severe Veno-Occlusive Disease (sVOD) with Multi-Organ Failure (MOF). Patients were enrolled at 36 US institutions between December 2007 and September 2009, 31 patients (30%) achieved a complete response (CR) by D+100, 33 patients (32%) survived to Day + 100 post SCT. Similar to the Phase III results, less sick patients responded better: patients who were not on dialysis or were not ventilator dependent at study entry had a higher CR rate compared to patients who were (41% vs 23%). In this population, no unexpected toxicities were observed and Defibrotide-associated toxicities were consistent with prior studies.

Dr. Richardson also reported in a poster presentation the results of a meta-analysis pooling data from matched patients with severe VOD with MOF in the Phase II and III studies (n= 133). Results were compared to the Historical Control (HC) group from the original Phase III study (N=32). Findings from this meta-analysis were consistent with results reported from previous studies; with improved outcomes of CR and survival by Day + 100 post SCT. CR in treated patients was 29% vs. 9% in the HC (p=0.0021 by propensity adjusted score), survival at Day + 100 was 40% vs. 25% (p= 0.0408). Similar with other studies, patients who were less severely compromised (those patients who were not on dialysis or ventilator dependent at study entry) had improved outcomes (CR rate 35% vs 10%; p=0.0006). The data presented by Dr. Richardson also supported the results of a recent randomized prophylactic study ( Corbacioglu et al, EBMT 2010), confirming that Graft-versus-Host Disease (GvHD) was less common in Defibrotide treated patients compared to HC (6% vs 25%).

Enrollment into the T-IND study continues and, following the amendment effective at the end of September 2009, entry criteria for the T-IND study were expanded to permit enrollment of patients with less severe VOD and VOD post chemotherapy.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,675.44 +2.84 0.02%
S&P 500 2,053.39 +1.57 0.08%
NASDAQ 4,760.00 +2.1210 0.04%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs